AXIM
AXIM Biotechnologies, Inc.
Price Chart
Latest Quote
$0.00
-0.00 (-38.18%)
Current Price
| Previous Close | $0.01 |
| Open | $0.01 |
| Day High | $0.01 |
| Day Low | $0.00 |
| Volume | 266,854 |
Stock Information
| Shares Outstanding | 340.46M |
| Total Debt | $6.78M |
| Cash Equivalents | $6K |
| Revenue | $93K |
| Net Income | $-4.14M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.16M |
| Exchange | OID |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $8.42M |
| Sales | $93K |
| Income | $-4.14M |
| Book/sh | $-0.03 |
| Cash/sh | $0.00 |
| Employees | 6 |
Financial Ratios
| Quick Ratio | 0.00 |
| Current Ratio | 0.00 |
Returns & Margins
| ROA | -36.27% |
| Gross Margin | 98.12% |
| Operating Margin | -3257.86% |
Ownership
| Insider Ownership | 22.39% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 12.46 |
| P/B | -0.11 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.01 |
| SMA50 | $0.01 |
| SMA200 | $0.01 |
| RSI | 30.30 |
| ATR | 0.0007 |
| Shares Float | 243.75M |
| Volatility | -0.24 |
| Rel Volume | 1.72 |
Performance History
| Week | -32.00% |
| Month | -32.00% |
| Quarter | -69.09% |
| 6 Months | -85.83% |
| YTD | -71.67% |
| Year | -51.43% |
| 3 Years | -84.55% |
| 5 Years | -99.53% |
| 10 Years | -99.17% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-04 | $0.00 | 266,854 |
| 2026-06-03 | $0.00 | 1,000 |
| 2026-06-02 | $0.00 | 1,100 |
| 2026-06-01 | $0.00 | 3,000 |
| 2026-05-29 | $0.01 | 44,100 |
| 2026-05-28 | $0.00 | 98,700 |
| 2026-05-27 | $0.00 | 7,300 |
| 2026-05-26 | $0.00 | 387,600 |
| 2026-05-22 | $0.01 | 125,900 |
| 2026-05-21 | $0.01 | 131,900 |
| 2026-05-20 | $0.01 | 10,400 |
| 2026-05-19 | $0.01 | 426,200 |
| 2026-05-18 | $0.00 | 1,045,000 |
| 2026-05-15 | $0.01 | 6,600 |
| 2026-05-14 | $0.01 | 27,900 |
| 2026-05-13 | $0.01 | 0 |
| 2026-05-12 | $0.01 | 22,400 |
| 2026-05-11 | $0.01 | 305,100 |
| 2026-05-08 | $0.01 | 182,600 |
| 2026-05-07 | $0.00 | 1,600 |
| 2026-05-06 | $0.00 | 39,400 |
| 2026-05-05 | $0.00 | 49,700 |
About AXIM Biotechnologies, Inc.
AXIM Biotechnologies, Inc. develops diagnostic healthcare solutions for ophthalmological conditions. It develops and commercializes two point-of-care diagnostic tests to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis, including ocular total immunoglobulin E allergy test and lactoferrin ADDE test. It also operates a full-service center for custom biomarker and biopharmaceutical research, custom assay development, clinical sample testing, and precision data delivery. In addition, the company develops a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring, as well as COVID-19 rapid diagnostic tools. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on AXIM.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $7,337 | $0 | - | - |
| Cost Of Revenue | $7,337 | $0 | - | - |
| Total Revenue | $70,458 | $39,518 | $8,875 | $60,460 |
| Operating Revenue | $70,458 | $39,518 | $8,875 | $60,460 |
| Expenses | ||||
| Interest Expense | $636,158 | $1,204,764 | $1,876,417 | $485,825 |
| Total Expenses | $1,833,537 | $2,790,357 | $4,661,647 | $7,789,025 |
| Other Income Expense | $-1,128,571 | $-4,104,079 | $285,983 | $-7,553,479 |
| Net Non Operating Interest Income Expense | $-636,158 | $-1,204,764 | $-1,876,160 | $-742,265 |
| Interest Expense Non Operating | $636,158 | $1,204,764 | $1,876,417 | $485,825 |
| Operating Expense | $1,826,200 | $2,790,357 | $4,661,647 | $7,789,025 |
| Other Non Operating Income Expenses | - | $-80,080 | - | - |
| Total Other Finance Cost | - | - | - | $257,466 |
| Other Operating Expenses | - | - | - | $-279,981 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-3,520,471 | $-8,059,682 | $-6,242,949 | $-16,024,309 |
| Net Interest Income | $-636,158 | $-1,204,764 | $-1,876,160 | $-742,265 |
| Normalized Income | $-2,391,900 | $-4,035,683 | $-6,528,932 | $-8,470,830 |
| Net Income From Continuing And Discontinued Operation | $-3,520,471 | $-8,059,682 | $-6,242,949 | $-16,032,305 |
| Total Operating Income As Reported | $-1,755,742 | $-2,750,839 | $-4,652,772 | $-13,974,998 |
| Net Income Common Stockholders | $-3,520,471 | $-8,059,682 | $-6,242,949 | $-16,032,305 |
| Net Income | $-3,520,471 | $-8,059,682 | $-6,242,949 | $-16,032,305 |
| Net Income Including Noncontrolling Interests | $-3,520,471 | $-8,059,682 | $-6,242,949 | $-16,032,305 |
| Net Income Continuous Operations | $-3,520,471 | $-8,059,682 | $-6,242,949 | $-16,024,309 |
| Pretax Income | $-3,520,471 | $-8,059,682 | $-6,242,949 | $-16,024,309 |
| Special Income Charges | $-38,688 | $-792,189 | $-479,573 | $-7,553,479 |
| Operating Income | $-1,763,079 | $-2,750,839 | $-4,652,772 | $-7,728,565 |
| Depreciation Amortization Depletion Income Statement | $432,394 | $427,019 | $426,126 | $2,115,687 |
| Depreciation And Amortization In Income Statement | $432,394 | $427,019 | $426,126 | $2,115,687 |
| Gross Profit | $63,121 | $39,518 | - | - |
| Interest Income | - | $0 | $257 | $1,026 |
| Interest Income Non Operating | - | $0 | $257 | $1,026 |
| Net Income Discontinuous Operations | - | - | $0 | $-7,996 |
| Per Share | ||||
| Diluted EPS | $-0.01 | $-0.03 | $-0.04 | $-0.12 |
| Basic EPS | $-0.01 | $-0.03 | $-0.04 | $-0.12 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-1,323,348 | $-2,403,900 | $-4,226,389 | $-5,869,318 |
| Total Unusual Items | $-1,128,571 | $-4,023,999 | $285,983 | $-7,553,479 |
| Total Unusual Items Excluding Goodwill | $-1,128,571 | $-4,023,999 | $285,983 | $-7,553,479 |
| Reconciled Depreciation | $432,394 | $427,019 | $426,126 | $2,115,687 |
| EBITDA (Bullshit earnings) | $-2,451,919 | $-6,427,899 | $-3,940,406 | $-13,422,797 |
| EBIT | $-2,884,313 | $-6,854,918 | $-4,366,532 | $-15,538,484 |
| Diluted Average Shares | $318,895,464 | $245,929,403 | $165,468,263 | $131,539,920 |
| Basic Average Shares | $318,895,464 | $245,929,403 | $165,468,263 | $131,539,920 |
| Diluted NI Availto Com Stockholders | $-3,520,471 | $-8,059,682 | $-6,242,949 | $-16,032,305 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Other Special Charges | $38,688 | $792,189 | $479,573 | $1,587,027 |
| Gain On Sale Of Security | $-1,089,883 | $-3,231,810 | $765,556 | - |
| Research And Development | $39,823 | $125,496 | $153,697 | $284,869 |
| Selling General And Administration | $1,353,983 | $2,237,842 | $4,081,824 | $5,668,450 |
| Impairment Of Capital Assets | - | - | $0 | $5,966,452 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-13,620,100 | $-11,251,628 | $-8,814,839 | $-6,722,073 |
| Total Assets | $3,447,296 | $4,121,548 | $4,212,035 | $5,323,435 |
| Total Non Current Assets | $3,446,541 | $3,965,091 | $4,108,056 | $4,686,822 |
| Non Current Prepaid Assets | $9,014 | $9,014 | $5,000 | $5,000 |
| Goodwill And Other Intangible Assets | $3,200,535 | $3,594,981 | $3,989,427 | $4,383,873 |
| Other Intangible Assets | $3,200,535 | $3,594,981 | $3,989,427 | $4,383,873 |
| Current Assets | $755 | $156,457 | $103,979 | $636,613 |
| Receivables | $510 | $0 | $0 | - |
| Accounts Receivable | $510 | $0 | - | - |
| Cash Cash Equivalents And Short Term Investments | $245 | $156,457 | $47,282 | $452,963 |
| Cash And Cash Equivalents | $245 | $156,457 | $47,282 | $452,963 |
| Cash Financial | $245 | $156,457 | $47,282 | $452,963 |
| Non Current Note Receivables | - | $0 | $0 | $104,268 |
| Prepaid Assets | - | $0 | $42,858 | $163,561 |
| Notes Receivable | - | $0 | $0 | - |
| Other Current Assets | - | - | $13,839 | $20,089 |
| Debt | ||||
| Net Debt | $7,040,854 | $5,506,277 | $5,597,671 | $6,189,290 |
| Total Debt | $7,181,901 | $5,894,607 | $5,664,742 | $6,719,124 |
| Long Term Debt And Capital Lease Obligation | $7,104,460 | $5,799,778 | $5,644,953 | $5,080,641 |
| Long Term Debt | $7,041,099 | $5,662,734 | $5,644,953 | $5,060,641 |
| Current Debt And Capital Lease Obligation | $77,441 | $94,829 | $19,789 | $1,638,483 |
| Current Debt | - | - | - | $1,581,612 |
| Other Current Borrowings | - | - | - | $1,126,919 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $13,866,861 | $11,778,195 | $9,037,447 | $7,661,635 |
| Total Non Current Liabilities Net Minority Interest | $7,104,460 | $5,799,778 | $5,644,953 | $5,080,641 |
| Current Liabilities | $6,762,401 | $5,978,417 | $3,392,494 | $2,580,994 |
| Other Current Liabilities | $4,115,975 | $2,482,723 | $1,648,831 | - |
| Current Deferred Liabilities | $731,878 | $598,297 | $380,845 | $0 |
| Payables And Accrued Expenses | $1,837,107 | $2,802,568 | $1,343,029 | $942,511 |
| Payables | $1,837,107 | $2,802,568 | $1,343,029 | $942,511 |
| Accounts Payable | $1,785,952 | $2,781,068 | $1,316,248 | $909,458 |
| Current Notes Payable | - | - | $0 | $454,693 |
| Other Payable | - | - | $26,781 | $32,873 |
| Non Current Deferred Liabilities | - | - | - | $0 |
| Non Current Deferred Taxes Liabilities | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $-10,419,615 | $-7,656,697 | $-4,825,462 | $-2,338,250 |
| Preferred Stock Equity | $50 | $50 | $50 | $50 |
| Total Equity Gross Minority Interest | $-10,419,565 | $-7,656,647 | $-4,825,412 | $-2,338,200 |
| Stockholders Equity | $-10,419,565 | $-7,656,647 | $-4,825,412 | $-2,338,200 |
| Retained Earnings | $-75,697,324 | $-72,184,858 | $-64,125,176 | $-57,882,227 |
| Other Equity Interest | - | $-24,475 | $89,000 | $4,530,000 |
| Other | ||||
| Ordinary Shares Number | $318,895,464 | $245,929,403 | $192,441,917 | $138,099,981 |
| Share Issued | $318,895,464 | $245,929,403 | $192,441,917 | $138,099,981 |
| Tangible Book Value | $-13,620,150 | $-11,251,678 | $-8,814,889 | $-6,722,123 |
| Invested Capital | $-3,378,516 | $-1,993,963 | $819,491 | $4,304,003 |
| Working Capital | $-6,761,646 | $-5,821,960 | $-3,288,515 | $-1,944,381 |
| Capital Lease Obligations | $140,802 | $231,873 | $19,789 | $76,871 |
| Total Capitalization | $-3,378,466 | $-1,993,913 | $819,541 | $2,722,441 |
| Additional Paid In Capital | $65,245,819 | $64,528,043 | $59,191,469 | $51,000,166 |
| Capital Stock | $31,940 | $24,643 | $19,295 | $13,861 |
| Common Stock | $31,890 | $24,593 | $19,245 | $13,811 |
| Preferred Stock | $50 | $50 | $50 | $50 |
| Long Term Capital Lease Obligation | $63,361 | $137,044 | $0 | $20,000 |
| Current Deferred Revenue | $731,878 | $598,297 | $333,125 | $0 |
| Current Capital Lease Obligation | $77,441 | $94,829 | $19,789 | $56,871 |
| Dueto Related Parties Current | $51,155 | $21,500 | $0 | $180 |
| Net PPE | $236,992 | $361,096 | $113,629 | $193,681 |
| Accumulated Depreciation | $-160,673 | $-122,725 | $-90,152 | $-58,473 |
| Gross PPE | $397,665 | $483,821 | $203,781 | $252,154 |
| Other Properties | $397,665 | $483,821 | $203,781 | $175,283 |
| Machinery Furniture Equipment | - | - | $183,992 | $175,283 |
| Buildings And Improvements | - | - | $19,789 | $76,871 |
| Properties | - | - | $0 | $0 |
| Goodwill | - | - | - | $0 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-857,897 | $-1,030,500 | $-2,053,036 | $-2,537,260 |
| Operating Activities | ||||
| Operating Cash Flow | $-855,058 | $-1,030,500 | $-2,044,326 | $-2,486,765 |
| Cash Flow From Continuing Operating Activities | $-855,058 | $-1,030,500 | $-2,044,326 | $-2,478,769 |
| Operating Gains Losses | $1,037,499 | $3,068,999 | $-499,445 | $1,587,027 |
| Cash From Discontinued Operating Activities | - | - | $0 | $-7,996 |
| Investing Activities | ||||
| Capital Expenditure | $-2,839 | - | $-8,710 | $-50,495 |
| Investing Cash Flow | $-2,839 | $0 | $-8,710 | $-50,495 |
| Cash Flow From Continuing Investing Activities | $-2,839 | $0 | $-8,710 | $-50,495 |
| Cash From Discontinued Investing Activities | - | - | $0 | $0 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $221,685 | $491,456 | $1,742,261 | $1,635,538 |
| Financing Cash Flow | $701,685 | $1,139,675 | $1,647,355 | $2,533,042 |
| Cash Flow From Continuing Financing Activities | $701,685 | $1,139,675 | $1,647,355 | $2,533,042 |
| Net Common Stock Issuance | $221,685 | $491,456 | $1,742,261 | $1,635,538 |
| Common Stock Issuance | $221,685 | $491,456 | $1,742,261 | $1,635,538 |
| Net Other Financing Charges | - | $-26,781 | $-86,706 | $7,504 |
| Other | ||||
| Repayment Of Debt | $0 | $0 | $-1,333,200 | $-120,000 |
| Issuance Of Debt | $480,000 | $675,000 | $1,325,000 | $1,010,000 |
| Interest Paid Supplemental Data | $0 | $0 | $177,500 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $245 | $156,457 | $47,282 | $452,963 |
| Beginning Cash Position | $156,457 | $47,282 | $452,963 | $457,181 |
| Changes In Cash | $-156,212 | $109,175 | $-405,681 | $-4,218 |
| Net Issuance Payments Of Debt | $480,000 | $675,000 | $-8,200 | $890,000 |
| Net Long Term Debt Issuance | $480,000 | $675,000 | $-8,200 | $890,000 |
| Long Term Debt Payments | $0 | $0 | $-1,333,200 | $-120,000 |
| Long Term Debt Issuance | $480,000 | $675,000 | $1,325,000 | $1,010,000 |
| Net PPE Purchase And Sale | $-2,839 | $0 | $-8,710 | $-40,495 |
| Purchase Of PPE | $-2,839 | $0 | $-8,710 | $-40,495 |
| Change In Working Capital | $783,070 | $1,292,282 | $1,039,419 | $-28,182 |
| Change In Other Working Capital | $-70,458 | $-29,998 | $333,125 | - |
| Change In Other Current Assets | $0 | $0 | $1,701 | $-20,089 |
| Change In Payables And Accrued Expense | $649,489 | $790,530 | $740,014 | $277,507 |
| Change In Payable | $649,489 | $790,530 | $740,014 | $277,507 |
| Change In Account Payable | $637,834 | $769,030 | $659,400 | $277,507 |
| Change In Prepaid Assets | $204,039 | $531,750 | $-55,510 | $-284,574 |
| Other Non Cash Items | $404,445 | $2,043,155 | $2,125,029 | $2,768,822 |
| Stock Based Compensation | $0 | $197,727 | $1,107,494 | $1,143,730 |
| Depreciation Amortization Depletion | $432,394 | $427,019 | $426,126 | $2,115,687 |
| Depreciation And Amortization | $432,394 | $427,019 | $426,126 | $2,115,687 |
| Amortization Cash Flow | $394,446 | $394,446 | $394,446 | $2,087,908 |
| Amortization Of Intangibles | $394,446 | $394,446 | $394,446 | $2,087,908 |
| Depreciation | $37,948 | $32,573 | $31,680 | $27,779 |
| Gain Loss On Investment Securities | $1,118,475 | $3,231,810 | $-765,556 | - |
| Net Income From Continuing Operations | $-3,512,466 | $-8,059,682 | $-6,242,949 | $-16,032,305 |
| Net Short Term Debt Issuance | - | - | $-90,000 | $-120,000 |
| Short Term Debt Payments | - | - | $-90,000 | $-120,000 |
| Net Intangibles Purchase And Sale | - | - | $0 | $-10,000 |
| Purchase Of Intangibles | - | - | $0 | $-10,000 |
| Change In Inventory | - | - | $20,089 | $-20,089 |
| Change In Receivables | - | - | $1,701 | $-1,026 |
| Asset Impairment Charge | - | - | $0 | $5,966,452 |
| Net Business Purchase And Sale | - | - | - | $0 |
| Sale Of Business | - | - | - | $0 |
| Unrealized Gain Loss On Investment Securities | - | - | - | $0 |
Fetched: 2026-02-02